ETP Ventures

SEIMEI is a premium brand of personalized nutrition and anti-aging technology. It has collaborated with Human Longevity Inc., an influential research institute in the field of intestinal health. China Baijia Medical, a longevity technology company, WuXi AppTec, a CRO, and Yipu, a user research company, have all joined forces. Ipsos Group (Ipsos), Silver Economic Think Tank Platform Ageclub, Zeno Technology (Establishing Senmei Zeno Synthetic Biology Joint Laboratory), and other industry leaders have reached a strategic agreement.

Deep Longevity, Inc. is a biotechnology company focused on developing innovative solutions for aging and longevity. Founded in 2016 and based in Hong Kong, the company specializes in creating aging and longevity clocks tailored for preventative medicine organizations, health clubs, insurance companies, and aging centers. Its offerings include Longevity Cloud, a platform that hosts deep aging clocks, and Young.AI, a web and mobile application designed to support longevity initiatives. Deep Longevity also develops multifactorial tools known as deep aging clocks to measure biological age, alongside a recommendation engine aimed at suggesting longevity interventions. The company employs advanced AI techniques to harness various data types, including clinical blood tests and other biological metrics, to enhance the accuracy of biological age predictions.

Dima Biotech is a tumor immunotherapy and monoclonal antibody developer, specializing in the development of recombinant monoclonal antibodies for tumor immune products and services. It has the unique RECmAb digital monoclonal antibody technology, which can be used to obtain a variety of genus and high quality. Monoclonal antibodies.

Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.